NCT04944953

To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.

Double-blinded, Randomized, Active Control, Single Center-designed, Phase I Clinical Trial to Evaluate the Safety and Efficacy for Improvement of Glabellar Lines of "HG-102" Compared to Botox® in Subjects With Moderate to Severe Glabellar Lines

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Hugel · Industry
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To compare the safety and efficacy of "HG-102" with Botox® in the improvement of moderate to severe glabellar lines.

Detailed description

Double-blinded, Randomized, Active control, Single center-designed, Phase I clinical trial to evaluate the safety and efficacy for improvement of Glabellar Lines of "HG-102" compared to Botox® in subjects with moderate to severe Glabellar Lines

Conditions

• Glabellar Lines

Interventions

Type	Name	Description
DRUG	Botulinum Toxin Type A Injection [Botox]	Single administration, Day 0, 20 units
DRUG	Botulinum toxin type A injection [HG-102]	Single administration, Day 0, 20 units

Timeline

• Start date: 2021-06-11
• Primary completion: 2021-09-02
• Completion: 2021-12-16
• First posted: 2021-06-30
• Last updated: 2022-05-24

Locations

1 site across 1 country: South Korea